The majority of colorectal cancer cells (53%) show mutation on KRAS, being characterized by the activation of both mitogen activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) signaling pathways28. The gene discussed is KRAS; the disease is colorectal cancer.